Edge Therapeutics Inc (NASDAQ:EDGE) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 1-year consensus price objective of $21.00 for the company and are forecasting that the company will post ($0.47) earnings per share for the current quarter, according to Zacks. Zacks has also given Edge Therapeutics an industry rank of 100 out of 265 based on the ratings given to related companies.
A number of equities research analysts have issued reports on the stock. BidaskClub cut shares of Edge Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Zacks Investment Research upgraded shares of Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price target for the company in a report on Monday, November 6th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. lifted its stake in shares of Edge Therapeutics by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 75,279 shares of the biotechnology company’s stock valued at $773,000 after buying an additional 532 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Edge Therapeutics by 16.9% in the second quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 1,733 shares during the period. California State Teachers Retirement System lifted its stake in shares of Edge Therapeutics by 7.7% in the second quarter. California State Teachers Retirement System now owns 35,167 shares of the biotechnology company’s stock valued at $361,000 after buying an additional 2,500 shares during the period. Rhumbline Advisers lifted its stake in shares of Edge Therapeutics by 19.1% in the second quarter. Rhumbline Advisers now owns 19,960 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 3,195 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Edge Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 3,764 shares during the period. Institutional investors and hedge funds own 50.26% of the company’s stock.
Edge Therapeutics (EDGE) traded down $0.17 during mid-day trading on Monday, reaching $9.23. 55,118 shares of the company’s stock were exchanged, compared to its average volume of 62,906. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.34 and a quick ratio of 8.34. Edge Therapeutics has a one year low of $7.30 and a one year high of $13.50.
Edge Therapeutics (NASDAQ:EDGE) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.11. equities analysts anticipate that Edge Therapeutics will post -1.7 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Zacks: Edge Therapeutics Inc (EDGE) Given Average Rating of “Strong Buy” by Analysts” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.com-unik.info/2017/12/07/zacks-edge-therapeutics-inc-edge-given-average-rating-of-strong-buy-by-analysts.html.
Edge Therapeutics Company Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Edge Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edge Therapeutics Inc and related companies.